全文获取类型
收费全文 | 480篇 |
免费 | 24篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 55篇 |
基础医学 | 59篇 |
口腔科学 | 13篇 |
临床医学 | 79篇 |
内科学 | 106篇 |
皮肤病学 | 14篇 |
神经病学 | 3篇 |
特种医学 | 106篇 |
外科学 | 26篇 |
综合类 | 7篇 |
预防医学 | 20篇 |
药学 | 26篇 |
肿瘤学 | 11篇 |
出版年
2019年 | 4篇 |
2018年 | 3篇 |
2017年 | 3篇 |
2016年 | 4篇 |
2015年 | 4篇 |
2014年 | 9篇 |
2013年 | 17篇 |
2012年 | 5篇 |
2011年 | 14篇 |
2010年 | 24篇 |
2009年 | 15篇 |
2008年 | 7篇 |
2007年 | 23篇 |
2006年 | 9篇 |
2005年 | 9篇 |
2004年 | 2篇 |
2003年 | 2篇 |
2002年 | 5篇 |
2001年 | 6篇 |
2000年 | 5篇 |
1999年 | 14篇 |
1998年 | 40篇 |
1997年 | 42篇 |
1996年 | 35篇 |
1995年 | 17篇 |
1994年 | 25篇 |
1993年 | 16篇 |
1992年 | 14篇 |
1991年 | 8篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 27篇 |
1987年 | 11篇 |
1986年 | 8篇 |
1985年 | 7篇 |
1984年 | 10篇 |
1983年 | 8篇 |
1982年 | 14篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1978年 | 3篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1954年 | 2篇 |
1952年 | 1篇 |
1948年 | 1篇 |
1947年 | 1篇 |
1943年 | 1篇 |
1870年 | 1篇 |
排序方式: 共有526条查询结果,搜索用时 11 毫秒
521.
Stel HV; Sakariassen KS; Scholte BJ; Veerman EC; van der Kwast TH; de Groot PG; Sixma JJ; van Mourik JA 《Blood》1984,63(6):1408-1415
We have studied the role of factor VIII-von Willebrand factor (FVIII- vWF) in both platelet adherence to subendothelium and ristocetin- induced platelet aggregation using monoclonal antibodies to human FVIII- vWF. Twenty-five monoclonal antibodies were obtained, two of which were directed to the factor VIII moiety of FVIII-vWF; one of these two completely inhibited the procoagulant activity (FVIII:C). The remaining 23 monoclonal antibodies were directed to the von Willebrand factor moiety of FVIII-vWF. The ability of the latter monoclonal antibodies to inhibit platelet adherence to arterial subendothelium was investigated with a perfusion model. According to the number of platelets adhering to the subendothelium, three groups of monoclonal antibodies could be discerned: (A) antibodies not affecting platelet adherence; (B) antibodies that inhibited platelet adherence to the level as observed when von Willebrand's disease plasma was tested; and (C) antibodies that completely inhibited both platelet adherence to subendothelium and ristocetin-induced platelet aggregation. The two antibodies present in group C competed for the same or closely related epitope(s) present on FVIII-vWF. These results demonstrate that a domain is present on the FVIII-vWF molecule that is associated both with ristocetin-induced aggregation and with the ability of FVIII-vWF to support platelet adherence to the subendothelium. Based on these observations, it is concluded that ristocetin-induced binding of FVIII-vWF to platelets reflects, at least in part, a physiologic mechanism regulating the function of FVIII-vWF in primary hemostasis. 相似文献
522.
Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors 总被引:10,自引:0,他引:10
Anderson DW; Epstein JS; Lee TH; Lairmore MD; Saxinger C; Kalyanaraman VS; Slamon D; Parks W; Poiesz BJ; Pierik LT 《Blood》1989,74(7):2585-2591
We wished to develop criteria for serological confirmation of human T- lymphotropic virus type I (HTLV-I) infection in healthy donors. Selected serum or plasma samples reactive by HTLV-I enzyme immunosorbent assay or gel-agglutination assays with at least one viral- specific band on Western immunoblot (WIB) were tested in six laboratories by four WIBs and four radioimmunoprecipitation assays (RIPAs) for antibodies to HTLV-I proteins encoded by gag (p19 and p24), env (gp46 and/or gp61), and tax (p40x) genes. One hundred forty-two donor sera were obtained from 38 Japanese, 69 American, and 35 Caribbean blood or plasma donors. Among these samples, WIB assays appeared more sensitive to p24 antibodies, whereas RIPAs were significantly more sensitive to gp61 antibodies. All sera (137) with gp61 antibodies had p24 antibodies. Of the 137 sera positive for p24 and gp61 antibodies, p19 antibodies were detected in 129 sera, and p40x antibodies were detected in 108. In sera with p19 antibodies and antibodies to env- or tax-encoded proteins, p24 antibodies were always present. Antibodies to p40x were not found in the absence of gp61 antibodies. Virological evidence of infection was found in seven American donors by lymphocyte coculture (one HTLV-I, one HTLV-II) or by polymerase chain reaction (three HTLV-I, two HTLV-II). Sera from all seven donors showed p24 and gp46 and/or gp61 antibodies. We suggest that seroreactivity to both p24 and gp46 and/or gp61 by WIB or RIPA or both are suitable criteria to confirm but not to distinguish HTLV-I and HTLV-II infections. 相似文献
523.
Abnormal erythroid progenitor cells in human preleukemia 总被引:1,自引:2,他引:1
Ten patients with preleukemia were studied by the erythroid cell clonal culture technique. In nine of these patients, erythroid colonies derived from peripheral blood BFU-E were not observed, while the other patient had markedly decreased peripheral blood BFU-E-derived erythroid colonies in vitro. In three patients, marrow cells were also cultured and no BFU-E-derived erythroid colonies were detected. These studies indicate that immature erythroid progenitor cells, BFU-E, in patients with preleukemia are either markedly decreased in number or grossly defective in their proliferative or differentiative capacities. 相似文献
524.
Ranolazine,a partial fatty acid oxidation (pFOX) inhibitor,improves left ventricular function in dogs with chronic heart failure 总被引:6,自引:0,他引:6
Sabbah HN Chandler MP Mishima T Suzuki G Chaudhry P Nass O Biesiadecki BJ Blackburn B Wolff A Stanley WC 《Journal of cardiac failure》2002,8(6):416-422
BACKGROUND: Abnormalities of energy metabolism are often cited as key elements in the progressive worsening of left ventricular (LV) dysfunction that characterizes the heart failure (HF) state. The present study tested the hypothesis that partial inhibition of fatty acids will ameliorate the hemodynamic abnormalities associated with HF. METHODS AND RESULTS: Chronic HF (LV ejection fraction 27 +/- 1%) was produced in 13 dogs by intracoronary microembolizations. Hemodynamic and angiographic measurements were made before and 40 minutes after intravenous administration of ranolazine, a partial fatty acid oxidation (pFOX) inhibitor. Ranolazine was administered as an intravenous bolus dose of 0.5 mg/kg followed by a continuous infusion for 40 minutes at a constant rate of 1.0 mg / kg / hr. Ranolazine significantly increased LV ejection fraction (27 +/- 1 versus 36 +/- 2, P =.0001), peak LV +dP/dt (1712 +/- 122 versus 1900 +/- 112 mm Hg/sec, P =.001), and stroke volume (20 +/- 1 versus 26 +/- 1 mL). These improvements occurred in the absence of any effects on heart rate or systemic pressure. In 8 normal healthy dogs, ranolazine had no effect on LV ejection fraction or any other index of LV function. CONCLUSIONS: In dogs with HF, acute intravenous administration of the pFOX inhibitor ranolazine improves LV systolic function. The absence of any hemodynamic effects of ranolazine in normal dogs suggests that the drug is devoid of any positive inotropic effects and acts primarily by optimizing cardiac metabolism in the setting of chronic HF. 相似文献
525.
526.
Prof. v. Biesiadecki 《Archives of dermatological research》1870,2(3):467-469
Ohne ZusammenfassungVorgelegt der Wiener Akademie der Wissenschaften am 7. April 1870. 相似文献